Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Microdosing Psychedelics to Improve Mood
Phase 2
Active, not recruiting
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo firstDrug: Psilocybin first
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Rotem Petranker
- Target Recruit Count
- 50
- Registration Number
- NCT05259943
- Locations
- 🇨🇦
Psych Research, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath